Gangcai Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gangcai Zhu has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Yong Liu
Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
26 shared publications Xueying Wang
Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha City, The People’s Republic of China
25 shared publications- Chao Liu
Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
21 shared publications - Diekuo Zhang
Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
21 shared publications - Guo Li
Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
21 shared publications - Helei Yan
Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
21 shared publications
Latest Publications
- 9 September 2026
- Published by Wiley in Immunology
- Vol. 179 (4) , 695-708
Prognostic Associations of BMI and Metabolic Syndrome With Outcomes After Anti‐ PD ‐1 Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma
To evaluate the associations of body mass index (BMI) and metabolic syndrome (MetS) with outcomes in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M‐NPC) receiving anti‐PD‐1 therapy, and to develop a prognostic model for overall survival (OS). This multicenter retrospective study included 238 patients with BMI ≥ 18.5 kg/m 2 from two Chinese hospitals. BMI and MetS associations were evaluated using center‐adjusted, center‐stratified, hierarchical, and quantitative sensitivity analyses. An OS nomogram was developed in the Xiangya cohort and externally evaluated in the Harbin cohort. In clinical confounder‐adjusted models with the exposures entered separately, high BMI was associated with OS (HR, 0.462; 95% CI, 0.324–0.657) and PFS (HR, 0.511; 95% CI, 0.380–0.688), and MetS was associated with OS (HR, 0.433; 95% CI, 0.278–0.674) and PFS (progression‐free survival) (HR, 0.616; 95% CI, 0.439–0.866). When BMI and MetS were jointly modelled, the MetS‐PFS association was attenuated (HR, 0.714; 95% CI, 0.504–1.012; p = 0.058). Exploratory biomarker analyses revealed group differences in combined positive score (CPS) and pan‐immune‐inflammation value (PIV). Center‐specific effect directions were consistent, but the external‐center calibration slope was 0.53 (95% CI, 0.08–0.98). Among anti‐PD‐1‐treated Chinese patients with R/M‐NPC and a BMI ≥ 18.5 kg/m 2 , higher BMI and MetS showed prognostic associations. These observational data do not establish causal or treatment‐predictive effects, and prospective validation in non‐Chinese populations across the full body‐weight spectrum is needed.
- 9 September 2026
- Published by Wiley in Immunology
- Vol. 179 (4) , 695-708
Prognostic Associations of BMI and Metabolic Syndrome With Outcomes After Anti‐ PD ‐1 Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma
To evaluate the associations of body mass index (BMI) and metabolic syndrome (MetS) with outcomes in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M‐NPC) receiving anti‐PD‐1 therapy, and to develop a prognostic model for overall survival (OS). This multicenter retrospective study included 238 patients with BMI ≥ 18.5 kg/m 2 from two Chinese hospitals. BMI and MetS associations were evaluated using center‐adjusted, center‐stratified, hierarchical, and quantitative sensitivity analyses. An OS nomogram was developed in the Xiangya cohort and externally evaluated in the Harbin cohort. In clinical confounder‐adjusted models with the exposures entered separately, high BMI was associated with OS (HR, 0.462; 95% CI, 0.324–0.657) and PFS (HR, 0.511; 95% CI, 0.380–0.688), and MetS was associated with OS (HR, 0.433; 95% CI, 0.278–0.674) and PFS (progression‐free survival) (HR, 0.616; 95% CI, 0.439–0.866). When BMI and MetS were jointly modelled, the MetS‐PFS association was attenuated (HR, 0.714; 95% CI, 0.504–1.012; p = 0.058). Exploratory biomarker analyses revealed group differences in combined positive score (CPS) and pan‐immune‐inflammation value (PIV). Center‐specific effect directions were consistent, but the external‐center calibration slope was 0.53 (95% CI, 0.08–0.98). Among anti‐PD‐1‐treated Chinese patients with R/M‐NPC and a BMI ≥ 18.5 kg/m 2 , higher BMI and MetS showed prognostic associations. These observational data do not establish causal or treatment‐predictive effects, and prospective validation in non‐Chinese populations across the full body‐weight spectrum is needed.
- Open Access
- 9 September 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 28143
Metabolic predictors of response to immunotherapy in locally advanced or metastatic esophageal cancer: unveiling the obesity paradox
- 9 September 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 28143
Open AccessMetabolic predictors of response to immunotherapy in locally advanced or metastatic esophageal cancer: unveiling the obesity paradox
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-31
Neuroimmune Interactions in Inflammatory Skin and Intestinal Diseases
The nervous and immune systems engage in intricate bidirectional interactions that constitute a central hub in the pathogenesis of cutaneous and intestinal inflammation. As primary barrier organs, the skin and gut share analogous structural and immunological features and are functionally linked through an integrated neuroimmune network and shared inflammatory signaling, forming the "skin-gut axis”. Nevertheless, comprehensive and systematic reviews that simultaneously address neurogenic inflammation in both the cutaneous and intestinal compartments remain scarce, and translational research targeting their reciprocal crosstalk is hampered by insufficient clinical evidence and inadequate target precision. In this narrative review, we focus on the neuroimmune mechanisms underlying neurogenic skin disorders, including atopic dermatitis, psoriasis, and rosacea. Given the strong association between intestinal inflammation and infection, we further summarize neuroimmune interactions in gut infectious inflammation, with particular emphasis on the unique innervation patterns of the intestine. Additionally, we discuss therapeutic strategies that target convergent and clinically relevant neuroimmune circuits shared by skin and gut inflammation. This review aims to provide a theoretical framework for deciphering the neuroimmune pathogenesis and stereotyped interconnections between skin and gut inflammation, and to inspire novel anti-inflammatory approaches that specifically modulate neuroimmune pathways.
- 1 September 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-31
Open AccessNeuroimmune Interactions in Inflammatory Skin and Intestinal Diseases
The nervous and immune systems engage in intricate bidirectional interactions that constitute a central hub in the pathogenesis of cutaneous and intestinal inflammation. As primary barrier organs, the skin and gut share analogous structural and immunological features and are functionally linked through an integrated neuroimmune network and shared inflammatory signaling, forming the "skin-gut axis”. Nevertheless, comprehensive and systematic reviews that simultaneously address neurogenic inflammation in both the cutaneous and intestinal compartments remain scarce, and translational research targeting their reciprocal crosstalk is hampered by insufficient clinical evidence and inadequate target precision. In this narrative review, we focus on the neuroimmune mechanisms underlying neurogenic skin disorders, including atopic dermatitis, psoriasis, and rosacea. Given the strong association between intestinal inflammation and infection, we further summarize neuroimmune interactions in gut infectious inflammation, with particular emphasis on the unique innervation patterns of the intestine. Additionally, we discuss therapeutic strategies that target convergent and clinically relevant neuroimmune circuits shared by skin and gut inflammation. This review aims to provide a theoretical framework for deciphering the neuroimmune pathogenesis and stereotyped interconnections between skin and gut inflammation, and to inspire novel anti-inflammatory approaches that specifically modulate neuroimmune pathways.
- Open Access
- 19 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (34)
USP14 competitively binds to FBXW7 to stabilize MTDH and promotes metastasis and drug resistance of head and neck squamous cell carcinoma
The development of metastasis marks an aggressive stage of head and neck squamous cell carcinoma (HNSCC) and is closely linked to unfavorable survival outcomes. While metadherin (MTDH) drives tumorigenesis, metastasis, and chemoresistance in HNSCC, its dysregulation mechanisms remain unclear. Here, we identify USP14 as a specific deubiquitinase that stabilizes MTDH. USP14-dependent deubiquitination of MTDH activates NF-κB signaling, which drives epithelial–mesenchymal transition and supports cancer stem cells maintenance, ultimately strengthening HNSCC metastasis and chemoresistance. Mechanistically, we uncovered a competitive interaction: USP14 competes with the ubiquitin ligase FBXW7 for MTDH binding, preventing FBXW7-mediated degradation. Consequently, USP14 inhibition significantly mitigates aggressive phenotypes, an effect reversed by MTDH reintroduction. Clinical analysis confirms that MTDH and USP14 are overexpressed and positively correlated in metastatic HNSCC tissues. In conclusion, our study reveals a regulatory axis where USP14 competitively counteracts FBXW7 to stabilize MTDH, driving HNSCC progression. These findings provide preclinical evidence that targeting USP14 is a promising therapeutic strategy to overcome metastasis and chemoresistance in HNSCC.
- 19 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (34)
Open AccessUSP14 competitively binds to FBXW7 to stabilize MTDH and promotes metastasis and drug resistance of head and neck squamous cell carcinoma
The development of metastasis marks an aggressive stage of head and neck squamous cell carcinoma (HNSCC) and is closely linked to unfavorable survival outcomes. While metadherin (MTDH) drives tumorigenesis, metastasis, and chemoresistance in HNSCC, its dysregulation mechanisms remain unclear. Here, we identify USP14 as a specific deubiquitinase that stabilizes MTDH. USP14-dependent deubiquitination of MTDH activates NF-κB signaling, which drives epithelial–mesenchymal transition and supports cancer stem cells maintenance, ultimately strengthening HNSCC metastasis and chemoresistance. Mechanistically, we uncovered a competitive interaction: USP14 competes with the ubiquitin ligase FBXW7 for MTDH binding, preventing FBXW7-mediated degradation. Consequently, USP14 inhibition significantly mitigates aggressive phenotypes, an effect reversed by MTDH reintroduction. Clinical analysis confirms that MTDH and USP14 are overexpressed and positively correlated in metastatic HNSCC tissues. In conclusion, our study reveals a regulatory axis where USP14 competitively counteracts FBXW7 to stabilize MTDH, driving HNSCC progression. These findings provide preclinical evidence that targeting USP14 is a promising therapeutic strategy to overcome metastasis and chemoresistance in HNSCC.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from CRB2 Activates an Epigenetic Axis to Promote Ferroptosis in Head and Neck Squamous Cell Carcinoma
STAT4 knockdown attenuates ferroptosis inducer-mediated CRB2 upregulation
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from CRB2 Activates an Epigenetic Axis to Promote Ferroptosis in Head and Neck Squamous Cell Carcinoma
STAT4 knockdown attenuates ferroptosis inducer-mediated CRB2 upregulation
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from CRB2 Activates an Epigenetic Axis to Promote Ferroptosis in Head and Neck Squamous Cell Carcinoma
Overall survival Cox regression analysis
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from CRB2 Activates an Epigenetic Axis to Promote Ferroptosis in Head and Neck Squamous Cell Carcinoma
Overall survival Cox regression analysis
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from CRB2 Activates an Epigenetic Axis to Promote Ferroptosis in Head and Neck Squamous Cell Carcinoma
CRB2 overexpression differentially regulates H4K20me2 occupancy at the SLC7A11 locus in Fadu cells
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from CRB2 Activates an Epigenetic Axis to Promote Ferroptosis in Head and Neck Squamous Cell Carcinoma
CRB2 overexpression differentially regulates H4K20me2 occupancy at the SLC7A11 locus in Fadu cells
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from CRB2 Activates an Epigenetic Axis to Promote Ferroptosis in Head and Neck Squamous Cell Carcinoma
Knockdown of CRB2 reduces the level of H4K20me2 by enhancing LSD1 expression
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from CRB2 Activates an Epigenetic Axis to Promote Ferroptosis in Head and Neck Squamous Cell Carcinoma
Knockdown of CRB2 reduces the level of H4K20me2 by enhancing LSD1 expression
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from CRB2 Activates an Epigenetic Axis to Promote Ferroptosis in Head and Neck Squamous Cell Carcinoma
H4K20me2 ChIP-seq-differentially genes in LSD1(E8A)-overexpressing vs. NC Fadu cells
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from CRB2 Activates an Epigenetic Axis to Promote Ferroptosis in Head and Neck Squamous Cell Carcinoma
H4K20me2 ChIP-seq-differentially genes in LSD1(E8A)-overexpressing vs. NC Fadu cells